Sadiqa Mahmood, DDS, MPH

Senior Vice President of Medical Affairs, Health Catalyst

Dr. Sadiqa Mahmood is Senior Vice President of Medical Affairs at Health Catalyst. She contributes to the overall vision and growth strategy of the Life Sciences business unit, and that of the organization in the US, UK, Europe, and Asia.

Dr. Mahmood is passionate about driving patient outcomes and engagement at the intersection of medicine, technology, analytics and data management. Dr. Mahmood works with the leadership across hospitals, pharma, biotech and digital health organizations to design population health and patient engagement programs,  data management and analytics strategy, and value and outcomes based initiatives. Previously Dr. Mahmood served as the Director of Clinical Analytics at the Dana-Farber Cancer Institute. Prior to joining DFCI, she served as the Director of Clinical Collaboration Program in the Department of Quality, Safety and Value at the Partners HealthCare System. Earlier, she served in clinical operations and quality improvement roles at Boston Medical Center and Children’s Hospital Boston. At Northeast Business Group on Health, she worked with hospitals and commercial health plans in the New York State to design a business model that presents a framework to design and operationalize initiatives for reduction in preventable hospital readmission rates. She worked as an analyst at the Harvard Law School’s Center for Health Law and Policy Innovation.

Dr. Mahmood is a dental surgeon, and has a Masters of Public Health degree from the Harvard School of Public Health. She is an author of over 20 peer-reviewed and scientific conference publications.

Speaker Sessions

15 – How Real-World Data Can Rescue Clinical Trials and Save Lives (Panel) (Clinical, Life Sciences; Course Level-Beginning)

Every year clinical trials of vital therapies are canceled, not because the therapy isn’t promising but because of issues with trial feasibility or cost. This hurts all stakeholders: patients, healthcare providers, and pharmaceutical companies. Making trials more cost-effective and feasible means improving the way participants are identified and enrolled while also cutting the time and labor of collecting data. Many researchers say real-world evidence in the form of multiple-source enterprise data warehouse (EDW) data is the answer, but this requires bridging some gaps in interoperability and security. Learn from panel experts who work in all facets of clinical trials in this discussion about the promises and challenges of integrating EDW data into clinical trials.